This invention relates to vaccines and in particular to the combination of non- integrating, replication-incompetent retroviral vectors (NIV) with virus-like particle (VLP) vaccines to induce an immune response in an animal host following administration to the host. This combination results in a novel vaccine strategy for delivering priming and boost doses, wherein an effective amount of an NIV is administered to the host, followed by an effective amount of a VLP. The concept can be broadly applied to infectious disease vaccines and also to cancer vaccines.
This invention relates to non-integrating, non-replicating retroviral vectors that cause an immune response in an animal host when administered to the host. The vectors transduce cells in the host, where they produce virus-like particles (VLPs), which stimulate an additional immune response in the host when they are released from the cells. The vectors are non-integrating, non-replicating retroviral vectors comprising long terminal repeats, a packaging sequence, and a heterologous promoter operably linked to one or more polynucleotide sequences that together encode the structural proteins of a virus. Methods of making and using the vectors are also disclosed.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
The invention relates to cell therapy for the treatment of HIV infection in humans. It provides a composition of genetically modified human cells for introduction into the body of a person infected with HIV, to reduce the person's viral load and to provide and reconstitute T-cells that are resistant to HIV infection. The composition comprises allogeneic or autologous human CD4+ T-cells, allogeneic or autologous human hematopoietic stem cells (HSCs), and allogeneic or autologous human mesenchymal stem cells (MSCs). Each cell comprises at least one heterologous anti-HIV sequence that inhibits HIV from infecting the cells or from replicating in the cells and at least one heterologous fate-controlling sequence. The invention also provides lentiviral vectors for making the cells, plasmids and producer cells for making the vectors, and methods for making the genetically modified cells.
A61P 31/18 - Antiviraux pour le traitement des virus ARN du HIV
A61K 31/711 - Acides désoxyribonucléiques naturels, c.-à-d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
This invention relates to making proteins in cultures of mammalian cells through the use of lentiviral vectors encoding the protein or proteins of interest. The invention provides a method for making a mammalian cell that produces a protein by transducing a mammalian cell with lentiviral transduction vectors at least 2 times in 24 hours, wherein each lentiviral transduction vector comprises an expressible polynucleotide coding for the protein. In one embodiment, the transduced cell is an apoptosis-resistant cell. The invention further provides mammalian cells and cell lines produced by this method as well as cultures of such cells. The invention also provides a method for making a protein by culturing these cells and cell cultures under conditions effective to produce the protein. The invention further provides an assay for measuring the concentration of a protein in a sample having a high concentration of the protein.
brevets